‘The dirty disease’ – both smokers and non-smokers get lung cancer. They face stigma on top of illness

Dr Jianni Tien

writer

Dr Jianni Tien

Postdoctoral Research Fellow, University of Sydney

Prof Alex Broom

writer

Prof Alex Broom

Professor of Sociology & Director, Sydney Centre for Healthy Societies, University of Sydney

Dr Katherine Kenny

writer

Dr Katherine Kenny

ARC DECRA Senior Research Fellow, University of Sydney

Dr Malinda Itchins

writer

Dr Malinda Itchins

Researcher, Department of Medical Oncology, Royal North Shore Hospital,, University of Sydney

Claim CPD for this activity

Educational Activities (EA)
0 minutes

These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

Reviewing Performance (RP)
0 minutes

These are activities that require reflection on feedback about your work.

Measuring Outcomes (MO)
0 minutes

These are activities that use your work data to ensure quality results.

EA
0 minutes

These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

RP
0 minutes

These are activities that require reflection on feedback about your work.

MO
0 minutes

These are activities that use your work data to ensure quality results.

Earlier this year, federal health minister Mark Butler announced a new national Lung Cancer Screening Program. The first of its kind for lung cancer, the screening program will open initially to current and former smokers aged 50 to 70 years by July 2025. It aims to save lives by detecting lung cancer earlier.

Since the 1980s, highly successful public health campaigns have raised awareness about the dangers of smoking and, in economically wealthy countries like Australia, the rate of smoking has dropped considerably.

Unfortunately, the success of anti-smoking campaigns has been accompanied by growing stigma around lung cancer. In fact, 28% of Australians admit they have less sympathy for lung cancer sufferers than those with other forms of cancer. And when it comes to an array of health issues, stigma negatively affects diagnosis, treatment and outcomes.

Patient support groups, professional associations and peak bodies are all in agreement that we need to rethink and modernise our understanding and approach to lung cancer, smoking and stigma.

More never-smokers are getting diagnosed

As well as the National Lung Cancer Screening Program, May saw the announcement of a nationwide ban on the sale of nicotine vapes in response to alarming increases in both vaping and smoking among young people. The vaping ban sparked a national conversation about the use of nicotine products, but little media attention has been paid to the lung cancer screening program.

Lung cancer is the fourth most diagnosed cancer in Australia and the leading cause of cancer-related death in Australia, followed by breast cancer.

While there is no disputing the link between lung cancer and smoking, nor the value of public health measures like the recent vaping ban, the proportion of people diagnosed with lung cancer who have never smoked – especially young women – is increasing. There is also growing recognition of other lung cancer risks such as environmental exposures and air pollution.

Despite this, lung cancer receives less funding (around 30% of what breast cancer receives) and is beset by poor screening, delayed diagnoses and low survival rates. The symptoms of lung cancer – including new cough, hoarse voice, coughing up blood, breathlessness, weightloss – can be missed and lead to diagnosis when the disease is already advanced.

Unfortunately, cancer as a disease is prone to various forms of moralising and many Australians think that ex-smokers “deserve” lung cancer as a consequence of their health behaviours.

But smoking and other so-called “lifestyle choices” are highly dependent on social status, family environment, wealth, and educational exposure over a lifetime.

Lung cancer disproportionately impacts people of Aboriginal and Torres Strait Islander heritage, those in regional and rural areas and those with lower socioeconomic backgrounds.

Smoking is not simply an individual choice, but rather is heavily influenced by one’s social context. Likewise, developing lung cancer, much like heart disease or diabetes, is not a personal or moral failing, despite having clear lifestyle links.

‘It’s the dirty disease’

In our recent study, we interviewed 14 women and 3 men aged 30–72 and recruited from social media. They spoke about undergoing treatment for lung cancer. In addition to dealing with their illness and treatment, they faced significant stigma:

“[…] it’s the first time I’ve really been aware of the sort of shame attached to an illness.”

Some participants spoke about the lack of funding for lung cancer:

“[…] people don’t donate to lung cancer because we’re not pretty. We’re stinky and tobacco-y.”

And of how public health campaigns had contributed to stigma and needed to be updated:

“They know young people are getting it out there and it’s just not hitting the press because it’s the ‘dirty disease’. There is so many young people. Who deserves to die, whether they’re smokers or not? I mean, it needs to be acknowledged.

There needs to be another campaign around: Why are so many people getting lung cancer when they’ve never smoked?”

Changing the conversation

The national lung cancer screening program is a step in the right direction to improve survival rates of lung cancer in Australia. But it’s important we confront the idea of lung cancer as a “dirty” disease, “brought on one’s self”.

The nationwide conversation around vaping provides as a good opportunity to do away with simplistic – and stigmatising – narratives about nicotine use that characterise it as weak or shameful. It’s time to disrupt assumptions about lung cancer being solely attributable to a person’s decisions to smoke. And we need to recognise the importance of supporting and caring for people experiencing ill-health regardless of lifestyle “choices”.The Conversation

Jianni Tien, Postdoctoral Research Fellow, University of Sydney; Alex Broom, Professor of Sociology & Director, Sydney Centre for Healthy Societies, University of Sydney; Katherine Kenny, ARC DECRA Senior Research Fellow, University of Sydney, and Malinda Itchins, Researcher, Department of Medical Oncology, Royal North Shore Hospital,, University of Sydney

This article is republished from The Conversation under a Creative Commons license. Read the original article.

The Conversation

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Expert panel - A/Prof Samantha Hocking, Prof John Dixon, facilitated by A/Prof Ralph Audehm

Expert panel - A/Prof Samantha Hocking, Prof John Dixon, facilitated by A/Prof Ralph Audehm

GLP-1 Prescribing Expert Panel Discussion

Prof Rukshen Weerasooriya

Prof Rukshen Weerasooriya

Arrhythmia Management in Primary Care

Dr Rupert Hinds

Dr Rupert Hinds

Infant Allergy Cases

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Share this

Share this

Dr Jianni Tien

writer

Dr Jianni Tien

Postdoctoral Research Fellow, University of Sydney

Prof Alex Broom

writer

Prof Alex Broom

Professor of Sociology & Director, Sydney Centre for Healthy Societies, University of Sydney

Dr Katherine Kenny

writer

Dr Katherine Kenny

ARC DECRA Senior Research Fellow, University of Sydney

Dr Malinda Itchins

writer

Dr Malinda Itchins

Researcher, Department of Medical Oncology, Royal North Shore Hospital,, University of Sydney

Test your knowledge

Recent articles

Latest GP poll

In general, do you support allowing non-GPs to refer to specialists in certain situations?

Yes, if the referral process involves meaningful collaboration with GPs

0%

Yes

0%

No

0%

Recent podcasts

Listen to expert interviews.
Click to open in a new tab

Find your area of interest

Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.

Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.